HIV/AIDS Medications: Research on Isentress
- Raltegravir Still Effective at 5 Years (July 26, 2011)
From HIVandHepatitis.com
- Another NRTI-Sparing Regimen Does Well in Treatment-Naive Patients (July 25, 2011)
From aidsmap.com
- Five-Year Follow-Up: Isentress Comparable to Sustiva (July 21, 2011)
From AIDSmeds.com
- Raltegravir Combined With Kaletra Associated With Good Preservation of Bone Density Over 96 Weeks (July 19, 2011)
From aidsmap.com
- Dose Optimisation: 50 mg Ritonavir-Boosting, 3TC Dosing and Raltegravir Once-Daily (May/June 2011)
To read PDF, click here.
In HIV Treatment Bulletin, from HIV i-Base
On TheBodyPRO.com
- Switching Isentress to Once a Day Is Less Effective (February 2011)
To read PDF, click here.
In Project Inform Perspective, from Project Inform
- Merck's HIV Drug Isentress Fails Once-a-Day Study (December 1, 2010)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
On TheBodyPRO.com
- HIV Drug Isentress Could Fight All Herpes Viruses (September 24, 2010)
From AIDSmeds.com
- Top Integrase Polymorphisms Do Not Confer Resistance to S/GSK1349572 or Raltegravir (September 15, 2010)
From National AIDS Treatment Advocacy Project
- Raltegravir Re-Use Response After Failure Depends on Mutation Pattern (September 15, 2010)
From National AIDS Treatment Advocacy Project
- Maintenance With Raltegravir/Atazanavir Usually Effective for 48 Weeks (Low Troughs, a Few Viral Rebounds) (September 13, 2010)
From National AIDS Treatment Advocacy Project
- Raltegravir Safe During Pregnancy (Summer/Fall 2010)
To read PDF, click here.
In Bulletin of Experimental Treatments for AIDS, from San Francisco AIDS Foundation
On TheBodyPRO.com
- Reyataz/Isentress Combo Spares Norvir and Nukes, but Is Integrase Resistance a Concern? (July 22, 2010)
From AIDSmeds.com
- Protease Inhibitor to Raltegravir Switch Maintains Viral Suppression, but NRTI Resistance Lowers Efficacy (July 22, 2010)
From aidsmap.com
- Raltegravir/Kaletra Combination Does Well (July 21, 2010)
A "nuke-sparing" combination of the integrase inhibitor raltegravir (Isentress) and the protease inhibitor drug lopinavir/ritonavir (Kaletra) looks highly promising, according to research presented to the conference.
From aidsmap.com
- New ViiV Integrase Inhibitor Effective Against Some Isentress-Resistant HIV Strains (July 20, 2010)
From AIDSmeds.com
- Protease Inhibitor-to-Isentress Switch Is Effective, Lipid Friendly (July 20, 2010)
From AIDSmeds.com
- Kaletra/Isentress Shows Promise as HIV Nuceleoside-Sparing Regimen for First-Line Treatment (July 20, 2010)
From AIDSmeds.com
- New Drugs and Simplified Treatments Demonstrate Potential for Treating HIV (AIDS 2010) (About Kaletra, Isentress, TBR-65 and S/GSK1349572) (July 20, 2010)
In The AIDS Beacon
- Raltegravir Lovefest, Vienna Edition: AIDS 2010 Studies Explore Various Strategies for Use -- A Blog Entry by Myles Helfand (July 20, 2010)
In The XVIII International AIDS Conference, from TheBody.com
On TheBodyPRO.com
- Raltegravir Resistance Pattern Critical in Early Response to S/GSK1349572 (July 19, 2010)
From National AIDS Treatment Advocacy Project
|
Advertisement
|
Email
Glossary
